CANNABIS SCIENCE Forum: Community User: isa

+4,20% !!!

+0,1360 $ !!!

0,1340 $ !!!

+3,2% !!!

0,1330 $ !!!

CBIS-Chart ist bullisch! Kaufsignal!

Guesto, du schreibst ja wieder nur dein 0815 Gesülse hier runter. Wieviel Zeit brauchst du noch um die Sache mit Crown Baus Capital mal ordentlich zu recherchieren. Bring mal was vernünftiges aufs Papier und hör auf Leute ins verderben zu stürzen. Wird Zeit das der Admin hier mal aufräumt.

Zu jeder Ausgabe von den Aktien steht: .....a fair market value of .... Die sehen also den wahren Wert einer ihrer Tesla super mega Zukunftsaktie Aktie bei 0,01 $ @Guesto, ich habe den ersten Cannabis Hype vor 3 Jahren miterlebt, als die Legalisierung für Colorado bevorstand. Aktien mit einem Wert von 0,01 Cent, sind innerhalb weniger Tage auf 120$ geschossen und noch schneller auf 0,01 Cent gefallen als man hätte reagieren können. Wenn du diese Aktie empfehlen willst, dann schreibe bitte über Fakten, news und Projekte die die Zukunft betreffen, vielleicht wirst du auch mich verbitterten Mann von deiner global beliebten T(HC)esla überzeugen

Ich hätte deren Anteile damals gerne übernommen, dann hätte ich nun ausgesorgt.

Schade Paulo, dann hat der Rocker ja erreicht, was er wollte. Good Luck!

@Stockrocker Hast Du damals über Tesla in der Gründungsphaye auch so hergezogen? Du scheinst ein verbitterter Mann zu sein.

Cannabis Science ist einer der beliebtesten Cannabis-Werte an der US-Börse und auch in Deutschland sehr gut handelbar. Ein sehr liquider Wert. Die Kursziele liegen bei über 20 Cent!

Stockrocker, falls Du es noch nicht weißt, wird an der Börse die Zukunft gehandelt.

Die haben sich alle samt in 6 Monaten zu Millionären gemacht. Mit wem seiner Kohle??? ;)

@Paolo.....Die Firma hat 2016 im Q3 sagenhafte 2900$ Umsatz gemacht. Die Führungsebene verkauft die Anteile die sie sich zu 0,01 $ je Aktie ausbezahlt haben, seit Oktober 16 zwischen 0,04 $ und 0,07 $...Vermutlich werden jetzt noch mehr Verkäufe folgen. CBIS ist nur ein Zock, mehr nicht! ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS During the three months ended March 31, 2016, we have issued securities using exemptions available under the Securities Act of 1933: As set out below, we have issued securities in exchange for private placements, services and for debt: On January 11, 2016, the Company issued 15,500,000 shares of R144 restricted common stock to Apothecary Genetics Investments with a fair market value of $181,350 for amendment to a property license agreement on February 9, 2012. On January 20, 2016, the Company issued 10,000,000 shares S-8 registered free-trading common stock under Option Agreement of 2015 Equity Award Plan with exercise price at $0.01 and a fair market value of $117,000 to a consultant. On February 1, 2016, the Company entered a management agreement with a consulting firm and agreed to issue 15,000,000 shares of R144 restricted common stock with a fair market value of $180,000 for investor relation services. The shares were issued on April 7, 2016. On February 7, 2016, the Company entered into a partial debt settlement agreement with Stacey R. Lewis to retire $45,854.71 of the $75,044 in promissory notes originated on March 21, 2015 and issued 45,000,000 shares of common stock to partially settle the debt for a loss on settlement of $588,645. 9 On February 22, 2016, the Company issued 7,000,000 shares S-8 registered free-trading common stock exercised under Option Agreement of the 2015 Equity Award Plan with exercise price at $0.01 and a fair market value of $86,100 to a consultant under management agreement for a total Stock Option of 25,000,000 common shares with fair market value of $307,500. On February 22, 2016, the Company issued 6,500,000 shares S-8 registered free-trading common stock exercised under Option Agreement of 2015 Equity Award Plan with exercise price at $0.01 and a fair market value of $79,950 to a consultant under management agreement for a total Stock Option of 25,000,000 common shares with fair market value of $307,500. On February 29, 2016, the Company issued 25,000,000 shares S-8 registered free--trading common stock under Option Agreement of 2016 Equity Award Plan with exercise price at $0.01 and a fair market value of $300,000 to a consultant under management agreement. On March 8, 2016, the Company issued 18,000,000 shares R144 restricted common stock to Raymond Dabney, CEO of the Company with a fair market value of $193,842 for bonus under November 5, 2014 management agreement. On March 8, 2016, the Company issued 20,000,000 shares R144 restricted common stock to MLS Lap BV, a company controlled a director of the Company with a fair market value of $215,380 for bonus under June 24, 2013 management agreement. On March 8, 2016, the Company issued 20,000,000 shares R144 restricted common stock to Chad Johnson, COO/General Council with a fair market value of $215,380 for bonus and services under November 25, 2014 agreement. On March 8, 2016, the Company issued 20,000,000 shares R144 restricted common stock to Robert Kane, CFO/director of the Company with a fair market value of $215,380 for bonus and services under January 20, 2015 agreement. On March 22, 2016, the Company issued 15,000,000 shares of S-8 registered free-trading common stock under Option Agreement of 2015 Equity Plan with exercise price at $0.01 and a fair market value of $226,500 to a consultant under management agreement. On March 22, 2016, the Company issued 5,000,000 shares of S-8 registered free-trading common stock under Option Agreement of 2016 Equity Plan with exercise price at $0.01 and a fair market value of $75,500 to a consultant under management agreement. On March 22, 2016, the Company issued 10,000,000 shares of S-8 registered free-trading common stock under Option Agreement of 2016 Equity Plan with exercise price at $0.01 and a fair market value of $151,000 to a consultant under management agreement. On March 22, 2016, the Company issued 15,000,000 shares of S-8 registered free-trading common stock under Option Agreement of 2016 Equity Plan with exercise price at $0.01 and a fair market value of $226,500 to a consultant under management agreement. On March 22, 2016, the Company issued 10,000,000 shares of S-8 registered free-trading common stock under Scientific Advisory Board Agreement of the 2016 Equity Plan with a fair market value of $151,000. On March 22, 2016, the Company issued 5,000,000 shares of S-8 registered free-trading common stock under Option Agreement of 2016 Equity Award Plan with exercise price at $0.01 and a fair market value of $75,500.

....und Selbstdarsteller....ist in jedem Forum der Lacher schlechthin...!